The initial 96 hours of invasive pulmonary aspergillosis: Histopathology, comparative kinetics of galactomannan and (1→3)-β-D-glucan, and consequences of delayed antifungal therapy

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4879-4886

  Hope, William W ^a,b   Petraitis, Vidmantas ^b,c,d   Petraitiene, Ruta ^b,c,d   Aghamolla, Tamarra ^c   Bacher, John ^e   Walsh, Thomas J ^b,d  

^a UNIVERSITY OF MANCHESTER   (United Kingdom)

^b NATIONAL CANCER INSTITUTE   (United States)

^c SAIC FREDERICK INC   (United States)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; CEFTAZIDIME; CYTARABINE; ENDO 1,3 BETA GLUCANASE; GALACTOMANNAN; GENTAMICIN; METHYLPREDNISOLONE; VANCOMYCIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL INFECTION; COMPARATIVE STUDY; CONIDIUM; CONTROL GROUP; CONTROLLED STUDY; EXPERIMENTAL MODEL; FEMALE; FUNGAL SPORE GERMINATION; FUNGUS HYPHAE; HISTOPATHOLOGY; INFLAMMATION; INOCULATION; KINETICS; LUNG ALVEOLUS MACROPHAGE; LUNG ASPERGILLOSIS; LUNG INFARCTION; LUNG WEIGHT; MATHEMATICAL MODEL; MOLECULE; MONTE CARLO METHOD; NONHUMAN; OPPORTUNISTIC INFECTION; PHAGOCYTOSIS; PRIORITY JOURNAL; RABBIT; SURVIVAL;

AMPHOTERICIN B; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLUS FUMIGATUS; BETA-GLUCANS; DEOXYCHOLIC ACID; DRUG COMBINATIONS; INVASIVE PULMONARY ASPERGILLOSIS; MANNANS; RABBITS;

EID: 78049283872     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00673-10     Document Type: Article

References (23)

1. Antachopoulos, C., J. P. Demchok, E. Roilides, and T. J. Walsh. 2010. Fungal biomass is a key factor affecting polymorphonuclear leukocyte-induced hyphal damage of filamentous fungi. Mycoses 53:321-328.
2. Capitano, B., B. A. Potoski, S. Husain, S. Zhang, D. L. Paterson, S. M. Studer, K. R. McCurry, and R. Venkataramanan. 2006. Intrapulmonary penetration of voriconazole in patients receiving an oral prophylactic regimen. Antimicrob. Agents Chemother. 50:1878-1880.
3. Clinical and Laboratory Standards Institute. 2002. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi. Approved standard M38-A. Clinical and Laboratory Standards Institute, Wayne, PA.
4. Cordonnier, C., C. Pautas, S. Maury, A. Vekhoff, H. Farhat, F. Suarez, N. Dhedin, F. Isnard, L. Ades, F. Kuhnowski, F. Foulet, M. Kuentz, P. Maison, S. Bretagne, and M. Schwarzinger. 2009. Empirical versus preemptive antifungal therapy for high-risk, febrile, neutropenic patients: a randomized, controlled trial. Clin. Infect. Dis. 48:1042-1051.
5. Cornely, O. A., J. Maertens, D. J. Winston, J. Perfect, A. J. Ullmann, T. J. Walsh, D. Helfgott, J. Holowiecki, D. Stockelberg, Y. T. Goh, M. Petrini, C. Hardalo, R. Suresh, and D. Angulo-Gonzalez. 2007. Posaconazole versus fluconazole or itraconazole prophylaxis in patients with neutropenia. N. Engl. J. Med. 356:348-359.
6. D'Argenio, D. Z., and A. Schumitzky. 1997. ADAPT II: a program for simulation, identification, and optimal experimental design: user manual. Biomedical Simulations Resource, University of Southern California, Los Angeles, CA.
7. Francis, P., J. W. Lee, A. Hoffman, J. Peter, A. Francesconi, J. Bacher, J. Shelhamer, P. A. Pizzo, and T. J. Walsh. 1994. Efficacy of unilamellar liposomal amphotericin B in treatment of pulmonary aspergillosis in persistently granulocytopenic rabbits: the potential role of bronchoalveolar D-mannitol and serum galactomannan as markers of infection. J. Infect. Dis. 169:356-368.
8. Garey, K. W., M. Rege, M. P. Pai, D. E. Mingo, K. J. Suda, R. S. Turpin, and D. T. Bearden. 2006. Time to initiation of fluconazole therapy impacts mortality in patients with candidemia: a multi-institutional study. Clin. Infect. Dis. 43:25-31.
9. Groll, A. H., C. A. Lyman, V. Petraitis, R. Petraitiene, D. Armstrong, D. Mickiene, R. M. Alfaro, R. L. Schaufele, T. Sein, J. Bacher, and T. J. Walsh. 2006. Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations. Antimicrob. Agents Chemother. 50:3418-3423.
10. Hope, W. W. 2009. Invasion of the alveolar-capillary barrier by Aspergillus spp.: therapeutic and diagnostic implications for immunocompromised patients with invasive pulmonary aspergillosis. Med. Mycol. 47(Suppl. 1):S291-S298.
11. Hope, W. W., G. L. Drusano, C. B. Moore, A. Sharp, A. Louie, T. J. Walsh, D. W. Denning, and P. A. Warn. 2007. Effect of neutropenia and treatment delay on the response to antifungal agents in experimental disseminated candidiasis. Antimicrob. Agents Chemother. 51:285-295.
12. Hope, W. W., M. J. Kruhlak, C. A. Lyman, R. Petraitiene, V. Petraitis, A. Francesconi, M. Kasai, D. Mickiene, T. Sein, J. Peter, A. M. Kelaher, J. E. Hughes, M. P. Cotton, C. J. Cotten, J. Bacher, S. Tripathi, L. Bermudez, T. K. Maugel, P. M. Zerfas, J. R. Wingard, G. L. Drusano, and T. J. Walsh. 2007. Pathogenesis of Aspergillus fumigatus and the kinetics of galactomannan in an in vitro model of early invasive pulmonary aspergillosis: implications for antifungal therapy. J. Infect. Dis. 195:455-466.
13. Hope, W. W., P. A. Warn, A. Sharp, S. Howard, M. Kasai, A. Louie, T. J. Walsh, G. L. Drusano, and D. W. Denning. 2006. Derivation of an in vivo drug exposure breakpoint for flucytosine against Candida albicans and Impact of the MIC, growth rate, and resistance genotype on the antifungal effect. Antimicrob. Agents Chemother. 50:3680-3688.
14. Leary, R., R. Jelliffe, A. Schumitzky, and M. van Guilder. 2001. An adaptive grid, non-parametric approach to pharmacokinetic and dynamic (PK/PD) models, p. 389-394. Proceedings of the Fourteenth IEEE Computer Society, Bethesda, MD.
15. MacCallum, D. M., and F. C. Odds. 2004. Need for early antifungal treatment confirmed in experimental disseminated Candida albicans infection. Antimicrob. Agents Chemother. 48:4911-4914.
16. Morrell, M., V. J. Fraser, and M. H. Kollef. 2005. Delaying the empiric treatment of Candida bloodstream infection until positive blood culture results are obtained: a potential risk factor for hospital mortality. Antimicrob. Agents Chemother. 49:3640-3645.
17. Ostrosky-Zeichner, L., B. D. Alexander, D. H. Kett, J. Vazquez, P. G. Pappas, F. Saeki, P. A. Ketchum, J. Wingard, R. Schiff, H. Tamura, M. A. Finkelman, and J. H. Rex. 2005. Multicenter clinical evaluation of the (1→3)β-D-glucan assay as an aid to diagnosis of fungal infections in humans. Clin. Infect. Dis. 41:654-659.
18. Petraitiene, R., V. Petraitis, A. H. Groll, T. Sein, S. Piscitelli, M. Candelario, A. Field-Ridley, N. Avila, J. Bacher, and T. J. Walsh. 2001. Antifungal activity and pharmacokinetics of posaconazole (SCH 56592) in treatment and prevention of experimental invasive pulmonary aspergillosis: correlation with galactomannan antigenemia. Antimicrob. Agents Chemother. 45:857-869.
19. Petraitis, V., R. Petraitiene, A. A. Sarafandi, A. M. Kelaher, C. A. Lyman, H. E. Casler, T. Sein, A. H. Groll, J. Bacher, N. A. Avila, and T. J. Walsh. 2003. Combination therapy in treatment of experimental pulmonary aspergillosis: synergistic interaction between an antifungal triazole and an echinocandin. J. Infect. Dis. 187:1834-1843.
20. Roilides, E., C. A. Lyman, J. Filioti, O. Akpogheneta, T. Sein, C. G. Lamaignere, R. Petraitiene, and T. J. Walsh. 2002. Amphotericin B formulations exert additive antifungal activity in combination with pulmonary alveolar macrophages and polymorphonuclear leukocytes against Aspergillus fumigatus. Antimicrob. Agents Chemother. 46:1974-1976.
21. Walsh, T. J., S. Goutelle, R. W. Jelliffe, J. A. Golden, E. A. Little, C. DeVoe, D. Mickiene, M. Hayes, and J. E. Conte, Jr. 2010. Intrapulmonary pharmacokinetics and pharmacodynamics of micafungin in adult lung transplant patients. Antimicrob. Agents Chemother. 54:3451-3459.
22. Wiederhold, N. P., L. K. Najvar, A. C. Vallor, W. R. Kirkpatrick, R. Bocanegra, D. Molina, M. Olivo, J. R. Graybill, and T. F. Patterson. 2008. Assessment of serum (1→3)-β-D-glucan concentration as a measure of disease burden in a murine model of invasive pulmonary aspergillosis. Antimicrob. Agents Chemother. 52:1176-1178.
23. Woods, G., M. H. Miceli, M. L. Grazziutti, W. Zhao, B. Barlogie, and E. Anaissie. 2007. Serum Aspergillus galactomannan antigen values strongly correlate with outcome of invasive aspergillosis: a study of 56 patients with hematologic cancer. Cancer 110:830-834.